Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.62 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.62 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474285 | 0.91 | RXRA (0.64) | RXRANR1H2NR1H3HTR2AHTR2C | |
| SCHEMBL3473491 | 0.91 | RXRA (0.68) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3472803 | 0.91 | RXRA (0.63) | RXRANR1H2NR1H3HTR2AHTR2C | |
| SCHEMBL3472950 | 0.91 | RXRA (0.63) | RXRANR1H2NR1H3HTR2AHTR2C | |
| SCHEMBL3471607 | 0.90 | RXRA (0.67) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3473514 | 0.90 | RXRA (0.67) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3473298 | 0.90 | RXRA (0.62) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3473291 | 0.90 | RXRA (0.67) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3472877 | 0.90 | RXRA (0.66) | RXRANR1H2NR1H3HTR2ADRD2 | |
| SCHEMBL3472992 | 0.89 | RXRA (0.66) | RXRANR1H2NR1H3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | claimed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130617-A1 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR | CHRM3, CHRM5, CHRM4 | RXRA 505/4885NR1H2 335/4885NR1H3 321/4885 |
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | RXRA 18/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.